Neubewertung Orphan > 30 Mio: Uveales Melanom, HLA-A*02:01-positiv
G-BA action
final resolution
2024-06-25
Evidence-checked summary
The G-BA issued a final resolution on 2024-06-25. The official page states that it took effect as follows: 27.06.2024. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
Patient group
Erwachsene mit einem inoperablen oder metastasierten uvealen Melanom und die HLA (humanes Leukozyten-Antigen)-A*02:01-positiv sind
Hint of considerable added benefit
Comparator
Therapie nach ärztlicher Maßgabe unter Berücksichtigung von - Dacarbazin, - Ipilimumab, - Lomustin, - Nivolumab, - Pembrolizumab
Official case record
No inferred stages
Consultation record
2024-04-08
75 parsed turns
Oral hearing: Tebentafusp (Neubewertung Orphan > 30 Mio: Uveales Melanom, HLA-A*02:01-positiv)
Official Wortprotokoll · 11 pages
IQWiG comparison
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
A23-128
matched
Tebentafusp (uveal melanoma) – Benefit assessment according to §35a Social Code Book
Official assessment PDF · 107 pages
G-BA decisions
2024-05-16
final resolution
The G-BA found a hint of considerable added benefit for Erwachsene mit einem inoperablen oder metastasierten uvealen Melanom und die HLA (humanes Leukozyten-Antigen)-A*02:01-positiv sind. The appropriate comparator was Therapie nach ärztlicher Maßgabe unter Berücksichtigung von - Dacarbazin, - Ipilimumab, - Lomustin, - Nivolumab, - Pembrolizumab. The G-BA issued a final resolution on 2024-05-16. The official page states that it took effect as follows: 16.05.2024. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
4 official documents · 4 cited claims
2024-06-25
final resolution
The G-BA issued a final resolution on 2024-06-25. The official page states that it took effect as follows: 27.06.2024. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 3 cited claims
Official sources